Gilead Sciences price target raised to $184 at BMO Capital
Moderately bullish analyst update, tempered by the lack of a stated rationale and the fact that targets are opinions.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Moderately bullish analyst update, tempered by the lack of a stated rationale and the fact that targets are opinions.
What happened, with direct paths to the underlying reporting
BMO Capital raised its GILD price target to $184 from a posted price of $165.61, implying about 11% upside to the target. The available facts do not provide the prior target or the analyst's rationale.
Target: $184
Posted price: $165.61
Analyst firm: BMO Capital
Analyst: Evan David Seigerman
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.